Esperion to Report Second Quarter 2024 Financial Results on August 12
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced it will report its second quarter 2024 financial results on Monday, August 12, 2024, before the market opens. Following the release, the company will host a webcast at 8:00 a.m. ET to discuss the financial results and provide business updates. Investors can pre-register for the conference call to obtain dial-in information, and a live audio webcast will be accessible on Esperion's website. The webcast replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is focused on discovering, developing, and commercializing innovative medicines for patients with or at risk for cardiovascular and cardiometabolic diseases. The company aims to help patients with high cholesterol reach their LDL-cholesterol reduction goals.
Positive
- Timely reporting of quarterly financial results
- Proactive investor communication through webcast and conference call
- Focus on innovative medicines for cardiovascular and cardiometabolic diseases
Negative
- None.
News Market Reaction
On the day this news was published, ESPR gained 3.85%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report its Q2 2024 financial results?
What time is Esperion's (ESPR) Q2 2024 earnings webcast scheduled for?
How can investors access Esperion's (ESPR) Q2 2024 earnings call?
What is Esperion's (ESPR) main focus in drug development?
